IL15 and B-cell chronic lymphocytic leukemia: Dose–response analyses involving several CLL populations (Figure 2B,C) confirm that the efficacy of these inhibitors at compromising CLL viability is strongly influenced by whether CLL cells received stimuli for growth: venetoclax is less effective on ODN + IL15-activated CLL cells, while conversely, YM155 shows greater efficacy.